<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02759224</url>
  </required_header>
  <id_info>
    <org_study_id>BR-LIC-CT-101</org_study_id>
    <nct_id>NCT02759224</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Pharmacokinetics of Lafutidine and Irsogladine Maleate Tablet</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open-Label, Randomized, Single-dose, 2x2 Crossover Study to Compare the Pharmacokinetics
      of BRI-1501 Tablet and Coadministration of Lafutidine and Irsogladine maleate as Individual
      Tablets in Healthy Adult Volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 15, 2016</start_date>
  <completion_date type="Actual">December 29, 2016</completion_date>
  <primary_completion_date type="Actual">July 1, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed concentration(Cmax) of Lafutidine and Irsogladine maleate</measure>
    <time_frame>0~36 hour after medication</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma drug concentration-time curve(AUClast) of Lafutidine and Irsogladine maleate</measure>
    <time_frame>0~36 hour after medication</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Gastric Ulcer</condition>
  <arm_group>
    <arm_group_label>Arm A (Lafutidine and Irsogladine maleate --&gt; BRI-1501)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects of Arm A take Lafutidine and Irsogladine maleate Individual tablets at 1st day as period I. And then, after wash out for 35 days, as period II, subjects of Arm A take a BRI-1501 tablet at 36th day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (BRI-1501 --&gt; Lafutidine and Irsogladine maleate)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects of Arm B take a BRI-1501 tablet at 1st day as period I. And then, after wash out for 35 days, as period II, subjects of Arm B take Lafutidine and Irsogladine maleate Individual tablets at 36th day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BRI-1501</intervention_name>
    <arm_group_label>Arm A (Lafutidine and Irsogladine maleate --&gt; BRI-1501)</arm_group_label>
    <arm_group_label>Arm B (BRI-1501 --&gt; Lafutidine and Irsogladine maleate)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lafutidine</intervention_name>
    <arm_group_label>Arm A (Lafutidine and Irsogladine maleate --&gt; BRI-1501)</arm_group_label>
    <arm_group_label>Arm B (BRI-1501 --&gt; Lafutidine and Irsogladine maleate)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irsogladine maleate</intervention_name>
    <arm_group_label>Arm A (Lafutidine and Irsogladine maleate --&gt; BRI-1501)</arm_group_label>
    <arm_group_label>Arm B (BRI-1501 --&gt; Lafutidine and Irsogladine maleate)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subject, aged 19- 50 years

        Exclusion Criteria:

          -  History of clinically significant and active disease

          -  History of gastrointestinal disease

          -  History of clinically significant hypersensitivity to study drug, any other drug

          -  Laboratory test serum AST or ALT &gt; 1.25 times of upper normal range serum total
             bilirubin &gt; 1.5 times of upper normal range eGFR &lt; 60 ml/min/1.73mÂ² serological
             test(HBsAg, HCV Ab, HIV Ag/Ab, Syphilis reagin) positive

          -  Hypotension or hypertension

          -  Pregnant or nursing women

          -  Participation in any other study within 90 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St.Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2016</study_first_submitted>
  <study_first_submitted_qc>April 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2016</study_first_posted>
  <last_update_submitted>February 6, 2017</last_update_submitted>
  <last_update_submitted_qc>February 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maleic acid</mesh_term>
    <mesh_term>Lafutidine</mesh_term>
    <mesh_term>Irsogladine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

